Shafique Virani

Former Chief Corporate Development OfficeratRecursion Pharmaceuticals· In proxies 2021–2023

Pay in FY2023+59% from the year before · Recursion Pharmaceuticals stock +27.9% the same year

Shafique Virani was paid $2.8M in FY2023 (Dec), up 59%. Recursion Pharmaceuticals stock rose 27.9% that year.

Pay$100 in the stock at the end of FY21 → $58

Pay is from the Summary Compensation Table of each Recursion Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

Recursion PharmaceuticalsPublic company · 5 yr
- Former Chief Corporate Development Officer2021 – Present · 5 yrStock in role -86%

Roles come from the proxy statements of each company.

Activity

Pay
Recursion Pharmaceuticals Former Chief Corporate Development Officer pay rose 59% to $2.8M. The stock rose 28% in FY2023 (Dec).
DEF 14AApr 23, 2024
Pay
Recursion Pharmaceuticals Former Chief Corporate Development Officer pay rose 157% to $1.8M. The stock fell 55% in FY2022 (Dec).
DEF 14AApr 23, 2024

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?